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a  b  s  t  r  a  c  t
Purpose: To evaluate the opportunities of single photon emission tomography/computerized
tomography (SPECT-CT) for localization of axillary sentinel lymph nodes (ASLNs) and sub-
sequent radiotherapy planning in women with early breast cancer.
Material and methods: Individual topography of ASLN was determined in 151 women with
clinical T1-2N0M0 breast cancer. SPECT-CT visualization of ASLNs was initiated 120 min after
intra-peritumoral injection of 99mTc-radiocolloids. Doses absorbed by virtual ASLNs after
the  whole breast irradiation with standard and extended tangential fields were calculated
on  a treatment planning station.
Results: SPECT-CT demonstrated a large variability of ASLN localization. They were detected
in  the central subgroup in 94 (61%) patients, in pectoral – in 77 (51%), and in interpectoral –
in  4 (3%) patients. Sentinel lymph nodes “lying on the chest” were revealed in 35 (23%) cases.
We  found that with standard tangential fields coverage of ASLNs was obtained only in 20%
of  evaluated women. Extended tangential fields can effectively irradiate ASLNs localized in
all  axillary sub-regions with the exception of ASLNs “lying on the chest”.Conclusion: SPECT-CT mapping of ASLNs in women with cT1-2N0M0 breast cancer reveals
their  variable localization. This information can be important for planning of radiation
treatment in women that underwent breast conserving surgery without an axillary surgery.
©  2019 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.1.  Background
Results of randomized trials indicate that radiation therapy
is an effective alternative to the axillary lymph node dis-
section in patients with breast cancer without clinical signs
of metastatic involvement of regional lymph nodes (LNs).1–3
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1507-1367/© 2019 Greater Poland Cancer Centre. Published by Elsevier Due to the orderly progression of breast cancer from primary
tumour to sentinel LNs (SLNs) these nodes can be considered
as the main target for regional radiotherapy.4 Furthermore, in
some women with early breast cancer, irradiation of axillary
SLNs (ASLNs) may be assumed as n̈ecessary and sufficient.̈
It has been mentioned in several papers that ASLN can be
effectively irradiated by tangential fields.5,6 At the same time,
it has been reported that the variability in SLNs topography
can cause significant decrease in the dose absorbed by axillary
LNs.7,8
B.V. All rights reserved.
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Fig. 1 – SPECT-CT axial views obtained after intratumoral injection of 99mTc-radiocolloids. (a) Sentinel lymph node located
in the apical subgroup of axillary lymph nodes (big yellow arrow). (b) Sentinel lymph node that corresponds to Sorgius
lymph node (red arrow).






















ectoral muscles. (b) Subpectoral sentinel lymph node.
Most of prior studies on axillary coverage by tangen-
ial fields used radiopaque markers placed at sites of the
emoved LNs. It was shown that individual patterns of lym-
hatic drainage and SLNs localization could be effectively
etermined by SPECT-CT examinations performed after intra-
umoral injection of radiocolloids.
Aim To assess individual variability of ASLNs localization
n women with breast cancer and to determine the way this
nformation can be used for treatment planning when consid-
ring simultaneous irradiation of the breast and ASLNs.
.  Material  and  methods
etween November 2013 and June 2015 SPECT-CT localization
f SLNs was performed in 186 non-treated women with cT1-
N0 breast cancer. In all patients, the results of clinical and
nstrumental examinations indicated no evidence of regional
Ns metastatic invasion. This single-center prospective study
as approved by Institutional Ethical Committee. Informed
onsents were obtained from all women before including
hem into the study.
The SPECT-CT visualization of ASLNs was initiated 120 min
fter intra-peritumoral injection of 0.2–0.4 ml  (100–300 MBq) of
9mTc labeled radiocolloids with particle size varied between
00 and 1000 nm.  The large sizes of labeled radiocolloidspermit preferential visualization of ASLNs without concomi-
tant accumulation of this compound in the second-echelon
LNs.
SPECT-CT examinations were performed with a high
resolution hybrid system (Symbia T16, Siemens, Germany)
supported by a low-energy high-resolution collimator. The
acquisition of the images was performed with a patient in
a position similar to the treatment position with the hands
abducted above the head.
SPECT-CT images were evaluated by an experienced
nuclear medicine specialist and radiation oncologist. They
determined anatomical location and the number of visualized
ASLNs. Taking into account that there is no conventional clas-
sification for various subgroups of axillary LNs in our study,
we distinguished 5 axillary LN subgroups depending on their
relationships with vessels and walls of the axillary cavity.9
The central LNs are embedded in adipose tissue in the cen-
ter of the axilla (Fig.1a). Pectoral LNs are located behind and
along the free border of the pectoralis major muscle (Sorgius
LN, Fig. 1b), as well as along the lower border of the pectoralis
minor muscle. Parts of them are located in the chest wall along
the lateral thoracic vessels (Fig. 2). The lateral subgroup of LN
is positioned on the outer wall of the axilla below the level of
the axillary vein. Subscapular subgroup of LNs lies on the pos-
terior wall of the axillary cavity along the subscapular vessels
(Fig. 3). The apical subgroup of LNs occupies the apex of the
690  reports of practical oncology and radFig. 3 – Sentinel lymph node visualized in subscapular
region (injection site marked by a white arrow).
axilla at the level of the upper border of the pectoralis minor
muscle and along the inferio-medial side of the axillary vein
(Fig. 4). Subclavian LNs were included into the apical subgroup.
Additionally, the interpectoral LNs and those located in
the vicinity of the chest wall were separately described. This
subgroup of axillary LNs is represented by subpectoral LNs
visualized behind the pectoral muscles at the level of the
first and second intercostal spaces (Fig. 2b), and pectoral LNs,
which are located in the vicinity of the chest wall (Fig. 5) along
the lateral thoracic vessels (at the level of the third and fourth
intercostal spaces).
To study the feasibility of the SLN irradiation by stan-
dard tangential fields, we took routine treatment plans of
10 consecutive patients with early breast cancer and then
performed modeling of different treatment techniques eval-
uating absorbed doses in various subgroups of potential SLN.
All 10 women underwent breast conserving surgery and were
candidates for the whole breast radiotherapy with tangential
fields. Breast volume in all 10 women was estimated as small
or medium and varied between 186 cm3 and 330 cm3. Rou-
tinely, all patients were simulated in the treatment position.
They were placed supine with the ipsilateral arm secured with
the immobilization device. Tangential fields were designed
in accordance with the following borders: cranial - 1–2 cm
above the contour of the breast, caudal - 1–2 cm below the
Fig. 4 – SPECT-CT images of the apical sentinel lymiotherapy 2 4 ( 2 0 1 9 ) 688–694
inframammary fold, anterior - 0.5 cm away from the breast
contour, posterior - along the edge of the lateral costal arch,
lateral - along the mid  axillary line, and medial - at the sterno-
clavicle joint.
Simulation was followed by cone beam computed tomog-
raphy and, then, the entire set of data was transmitted to
3D planning system («Oncentra»,  Elekta, Sweden). CT of every
woman was used as a model for virtual simulation of different
radiotherapy techniques with different radiotherapy fields. In
the treatment planning system, on CT slices of each of 10
models additional areas of interest were outlined around a sin-
gular LN which corresponded to SLN of the above mentioned
axillary LN subgroups. LNs that represented every subgroup
of axillary LNs were drawn in accordance with their rela-
tion to the corresponding vessels. These representatives of
SLN of 5 above mentioned subgroups were called “virtual
SLN”.
After planning a standard tangential irradiation of the
breast (25 fraction of 2 Gy), we  evaluated the absorbed
dose in all above mentioned virtual SLNs: central, pectoral,
interpectoral subregions and SLNs located in the vicinity
of the chest wall. In our study, pectoral SLNs were rep-
resented by LNs near the border of the pectoralis major
muscle (Sorgius LN). Lymph nodes located in the vicinity
of the chest wall were examined separately and were sub-
divided into subpectoral SLNs (at the level of the first and
second intercostal spaces) and LNs lying along lateral tho-
racic vessels (at the level of the third and fourth intercostal
spaces).
At the next stage, extended (modified) tangential fields
were generated for each woman using the same cone beam
CT data. For this 3D treatment plan, the superior radiation
field border was set at the inferior margin of the humeral
head. Remaining borders were similar to those for standard
tangents. Gantry and collimator angles were slightly modified
in order to improve the coverage of LNs and minimize a dose
to the lung.
Finally, after standard and extended tangential fields, we
generated 3D treatment plans for intensity modulated radi-
ation therapy (IMRT) for all 10 women. We used a forward
planning technique. Breast tissue and SLN of every axillary
subregion were determined as CTV with prescribing dose
homogeneity between 95% and 110%. Constraints to critical
organs were as follows: mean dose to the ipsilateral lung
below 9 Gy, V20Gy<10%, mean dose to the heart below 7 Gy,
ph nodes (axial, sagittal and coronal views).
reports of practical oncology and radiotherapy 2 4 ( 2 0 1 9 ) 688–694 691
Fig. 5 – Fused SPECT-CT images in transverse and sagittal views, showing pectoral sentinel lymph node located “on the
thoracic wall” (arrow).
Table 1 – Localization of visualized sentinel lymph nodes according to various axillary subgroups.
Localization of sentinel lymph nodes Absolute number of
observations
Relative frequency (in 151
women with visualized
axillary sentinel nodes)
Central only 63 41%
Central + pectoral 21 14%
Central + pectoral + apical 4  3%
Central + lateral 1  1%





























Pectoral only 48 
Pectoral + apical 4 
Lateral only 5 
20Gy<10%, V30Gy<5%. Thus, the task of delivering an ade-
uate dose to the breast tissue and to all above mentioned
irtual SLNs, first of all to SLNs “on the chest wall”, was solved.
.  Results
 successful SPECT-CT visualization of SLNs was obtained in
51 (81%) out of 186 examined patients. As could be expected,
LNs were most frequently identified in the central subgroup
f axillary LNs (94 patients; 62%). In 116 women SLNs were
etected in only one subgroup of axillary nodes, in other
5 patients they were mentioned in two or more  subgroups
Table 1). Sentinel LNs of the central subgroup were only
hose accumulating radiocolloids in 63 cases (41%), although
n other observations we revealed a combination of SLNs in
he central and other subgroups of axillary LNs. Somewhat
ess frequently, in 77 (50%) women, SLNs were located in the
ectoral subgroup of LNs. In 48 (31%) patients, it was presented
nly as SLN of this subgroup, in the rest of them - by a combina-
ion with other subgroups. The SLN location close to the chest
all (“on the chest wall”) was detected in 35 (23%) out of 151
atients, among them 17 (11%) patients presented with SLNs
isualized in the subpectoral subgroup at the level of the first-
econd intercostal spaces. In other 18 (12%) patients, they were
ocated at the level of the third and fourth intercostal spaces
long the a. thoracica lateralis. It was mentioned that visual-
zation of subpectoral SLNs at the first and second intercostal
paces in 14 (82%) cases was accompanied by the detection
f SLN located near the border of the pectoralis major mus-
le (Sorgius LN) and/or by SLN in the central subgroup. Such31%
3%
3%
a combination was found only in 7 (39%) out of 18 patients
with SLN localization “on the chest wall” at the third or fourth
intercostal spaces.
In 4 of 151 evaluated women, ASLNs were visualized in the
interpectoral space. In 15 cases SPECT-CT detected ASLNs in
the subscapular and apical regions. In all cases, their detection
by SPECT-CT was accompanied by visualization of LNs  in the
central or pectoral subgroups.
Radiotherapy plans for the whole breast irradiation by
standard tangential fields were generated for 10 patients
(Table 2). Analysis of this plans demonstrated that the mean
dose absorbed by SLNs defined in the central and subpec-
toral regions, as well as by SLNs located close to the edge of
the chest wall at the third-fourthintercostal spaces, did not
exceed 4.8 Gy, i.e. it was significantly lower than tumorici-
dal radiation dose. The mean dose delivered to Sorgius LN
which represented SLN of the pectoral subgroup amounted
to 46.6 Gy–52.1 Gy in two patients and did not exceed 25.5 Gy
in 8 patients. The mean dose absorbed by the SLNs located in
the projection of the lateral subgroup was 53 Gy in one patient
and did not exceed 2.7 Gy in 9 patients. The mean dose deliv-
ered to the interpectoral SLNs was 42.5 Gy in one case and less
than 33.3 Gy in 9 patients.
3D treatment plans for irradiation of the breast with
extended (modified) tangential fields were generated with the
account for topography of different SLNs defined in various
axillary LN subgroups. The main goal of these treatment plans
was the irradiation of the remaining breast tissue and ASLNs
of different localizations. The mean doses delivered to SLNs
by extended tangential fields are presented in Table 3. First of
all, it should be noted that the mean doses delivered to SLNs of
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Table 2 – Mean dose absorbed by virtual sentinel lymph nodes located in various axillary subgroups. 3D modeling of
breast radiotherapy using standard tangential fields.
Case no. (Name) Cent.a Pecta (S) Pecta (Th II) Pecta (Th III) Pecta (Th IV) IPa Lata Lung (V20 Gy; %)
1 (N) 4.3 (8.6%) 52.1 (104.2%) 2.9 (5.8%) 1.8 (3.6%) 1.7 (3.4%) 33.2 (6.64%) 53.1 (106.2%) 1,3 (2.6%)
2 (M) 0.6 (1.2%) 0.8 (1.6%) 0.7 (1.4%) 1.3 (2.6%) 2.5 (5%) 0.9 (1.8%) 0.8 (1.6%) 0
3 (L) 2.6 (5.2%) 25.5 (51%) 1.3 (2.6%) 1.1 (2.2%) 1.2 (2.4%) 15.1 (30.2%) 6.4 (12.8%) 0
4 (C) 0.5 (1%) 0.4 (0.8%) 0.7 (1.4%) 0.9 (1.8%) 0.9 (1.8%) 0.8 (1.6%) 0.5 (1%) 0
5 (MA) 1.2 (2.4%) 46.6 (93.2%) 2.4 (4.8%) 1.2 (2.4%) 2.3 (4.6%) 5.8 (11.6%) 6.9 (13.8%) 0
6 (R) 0.8 (1.6%) 1.2 (2.4%) 1.2 (2.4%) 1.1 (2.2%) 1.2 (2.4%) 10 (20%) 0.7 (1.4%) 0
7 (T) 1.4 (2.8%) 19.2 (38.4%) 1.9 (3.8%) 1.8 (3.6%) 2.9 5.8%) 4.6 (9.2%) 1.1 (2.2%) 0
8(Z) 3.4 (6.8%) 21.9 43.8%) 3.9 (7.8%) 2.7 (5.4%) 4.8 (9.6%) 42.5 (85%) 2.7 (5.4%) 1%
9 (A) 0.6 (1.2%) 0.5 (1%) 0.7 (1.4%) 0.6 (1.2%) 0.8 (1.6%) 0.7 (1.4%) 0.9 (1.8%) 0
10 (MI) 0.7 (1.4%) 1.1 (2.2%) 0.6 (1.2%) 0.8 (1.6%) 1.2 (2.4%) 1.5 (3%) 0.4 (0.8%) 1.4%
Cent, virtual sentinel lymph node localized in the central subgroup.
Pect (S), virtual sentinel lymph node represented by Sorgius lymph node localized in the pectoral subgroup.
Pect (Th II) virtual subpectoral sentinel lymph node localized in the pectoral subgroup close to the thoracic wall (opposite to II rib).
Pect (Th III) virtual sentinel lymph node localized in the pectoral subgroup close to the thoracic wall (opposite to III rib).
Pect (Th IV) virtual sentinel lymph node localized in the pectoral subgroup close to the thoracic wall (opposite to IV rib).
IP, virtual intrapectoral sentinel lymph node localized between pectoral muscles.
Lat, virtual sentinel lymph node localized in the lateral subgroup.
Lung (V20Gy; %), relative volume (%) of the ipsilateral lung absorbed the dose above 20 Gy.
a Absorbed dose in Gy (absorbed dose in percents of prescribed 50 Gy).
Table 3 – Mean dose absorbed by virtual sentinel lymph nodes located in various axillary subgroups. 3D modeling of
breast radiotherapy using modified (high) tangential fields.
Case no. (Name) Cent. Pect (S) Pect (Th II) Pect (Th III) Pect (Th IV) IP Lat Lung (V20Gy;%)
1 (N) 45.3 (90.6%) 52.1 (104.2%) 43.9 (87.8%) 14.5 (29%) 4.8 (9.6%) 51.4 (102.8%) 47.3 (94.6%) 6.7%
2 (M) 43.5 (87%) 46.7 (93.4%) 41.3 (82.6%) 18.2 (36.4%) 45.2 (90.4%) 45.8 (91.%) 42.2 (84.4%) 12.9%
3 (L) 45.9 (91.8%) 50.4 (100.8%) 44 (88%) 3.2 (6.4%) 3.1 (6.2%) 50.1 (100.2%) 31 62% 13.4%
4 (C) 40 (80%) 41.1 (82.2%) 40.3 (80,6%) 22.2 (44.4%) 7.3 (14.6%) 42.3 (84.6%) 41.6 (83.2%) 10%
5 (MA) 45.2 (90.4%) 56.4 (112.8%) 45.6 (91.2%) 7.2 (14.4%) 25.9 (51.8%) 47.7 (95.4%) 43.1 (86.2%) 6.2%
6 (R) 42.7 (85.4%) 49 (98%) 49.4 (98.8%) 41.8 (83.6%) 10.3 (20.6%) 52 (104%) 40.6 (81.2%) 9.8%
7 (T) 48.5 (91.6%) 53.1 (106.2%) 46.2 (92.4%) 8.3 (16.6%) 19.1 (38.2%) 50.2 (100.4%) 42.8 (85.6%) 13%
8(Z) 43.2 (86.4%) 48 (96%) 44.3 (88.6%) 44.3 (88.6%) 41.2 (82.4%) 47.2 (94.4%) 45.3 (90.6%) 19%
9 (A) 35.8 (71.6%) 45.7 (91.4%) 40.2 (80.4%) 2.2 (4.4%) 2.4 (4.8%) 44.7 (89.4%) 40.1 (80.2%) 11.5%
10 (MI) 47.8 (95.6%) 52.5 (105%) 43.4 (86.8%) 17.5 (35%) 8 (16%) 51.7 (103.4%) 26.2 (52.4%) 8.2%
Cent, virtual sentinel lymph node localized in the central subgroup.
Pect (S), virtual sentinel lymph node represented by Sorgius lymph node localized in the pectoral subgroup.
Pect (Th II) virtual subpectoral sentinel lymph node localized in the pectoral subgroup close to the thoracic wall (opposite to II rib).
Pect (Th III) virtual sentinel lymph node localized in the pectoral subgroup close to the thoracic wall (opposite to III rib).
Pect (Th IV) virtual sentinel lymph node localized in the pectoral subgroup close to the thoracic wall (opposite to IV rib).
IP, virtual intrapectoral sentinel lymph node localized between pectoral muscles.
Lat, virtual sentinel lymph node localized in the lateral subgroup.
the d
.
breast tissues. It was assumed that simultaneous irradiationLung (V20Gy; %), relative volume (%) of the ipsilateral lung absorbed 
*Absorbed dose in Gy (absorbed dose in percents of prescribed 50 Gy)
interpectoral, subpectoral or pectoral (Sorgius LN) localization
exceeded 40 Gy in all cases and were identified as conditionally
tumoricidal. The estimated mean dose in the projection of the
central and lateral subgroups of axillary LNs was lower than
the planned dose in two cases: 40 Gy and 35.8 Gy vs. 26.2 Gy
and 31 Gy, respectively. It should be emphasized that despite
the increase in the depth of the extended tangential fields
(10–20 mm in the direction from the chest wall to the lung), the
percentage of ipsilateral lung volume irradiated with a total
dose of 20 Gy and more  was 19% in only one patient, and did
not exceed 13% in the other nine cases.
However, the irradiation of pectoral SLNs located on the
chest wall at the 3rd and 4th intercostal spaces with a total
dose of more  than 40 Gy, was achieved only in two cases of
using the extended tangential fields. In the remaining eightose above 20 Gy.
cases the total dose absorbed in the projection of SLNs defined
in this axillary subgroup did not exceed 25.9 Gy.
4.  Discussion
Currently, there are at least two randomized trials10,11 investi-
gating whether surgical dissection in women with early breast
cancer without clinical (palpation and US) signs of axillary LN
involvement can be omitted and substituted by breast con-
serving surgery with tangential radiotherapy to the remainingof axillary SLN could be an important part of this treatment
strategy that should provide a reliable loco-regional control. In
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nd determine high variability of axillary SLN localization.
dditionally, with the help of 3D modeling of various radi-
tion fields we  demonstrate that standard tangential fields
sually do not permit adequate coverage of axillary SLN. On
he contrary, extended tangential fields are able to cover SLN in
entral and pectoral axillary subregions in most cases. Unfor-
unately, SLN localized in the III-IV intercostal spaces “close
o the chest wall” are very rarely covered by any tangential
elds and must be irradiated by newer techniques, for exam-
le, IMRT.  On the basis of this data we propose that in patients
hat are treated without surgical interventions on axillary LN
PECT-CT visualization of SLN can be an important part of
ndividual radiotherapy planning.
During the last decades, a strong evidence has been
btained that the breast conserving surgery supplemented
y tangential radiotherapy to the remaining breast tissue in
atients with metastatic involvement of one or two axillary
LNs could achieve high rates of overall and disease-free sur-
ival comparable to those obtained after ALND.12,13
It was suggested that the high rates of locoregional con-
rol (99%) in patients with limited metastatic involvement
f axillary LNs (1–2 SLNs) who  did not undergo ALND may
e associated with post-operative radiotherapy, in particular,
ith the irradiation of the remaining breast tissues by high
angential fields.6
Sentinel LN irradiation in patients with early stage breast
ancer without clinical evidence of axillary metastases may
e sufficient to achieve a reliable regional control.10,11 Our
ata show that with tangential fields irradiation of axillary
LNs located in the projection of central and subpectoral sub-
roups is possible only in 20% of cases. The literature has also
ointed out that standard tangential fields, in most cases, do
ot allow for adequate irradiation of axillary SLNs.5,14 How-
ver, van Roozendaal et al.15 determined localization of SLN
ith the help of SPECT-CT and/or surgical clips and found that
ith the use of 3D radiotherapy the site of SLN was treated
ith elective dose in 76% of women. They also mentioned that
he size of the breast and body mass index did not influence
he dose at the SLN site. Schlembach et al.7 reported that dur-
ng standard tangential irradiation the clips placed to mark
he location of removed SLNs were encompassed by the 95%
sodose in 85% of cases. Similar results have been reported
y other authors.16–18 Nevertheless, Rabinovitch et al.8 men-
ioned a significant variability in topography of the removed
LNs which were located at the level of 3–5 thoracic verte-
ras in 87% of cases and at the level of 6–7 thoracic vertebra
n the remaining 13% cases. Alco et al. underlined that only
areful planning of tangential field geometry combined with
he use of multileaf collimators could increase the mean dose
o axillary LNs.19 Our results of preoperative visualization of
LNs also indicate a substantial variability in their topogra-
hy: localization of SLNs in the central and pectoral subgroups
orresponded to the standard expectations in 61% and 50% of
ases, respectively. In addition, modeling of various radiation
elds and techniques demonstrated a large variability in the
oses absorbed by SLNs of different localization. These data
upport the proposal that SPECT-CT visualization of SLNs can
e a useful tool for radiotherapy planning in women with early
reast cancer, especially in those cases when we  plan to cover
SLNs by the fields designed for the whole breast irradiation.therapy 2 4 ( 2 0 1 9 ) 688–694 693
This option can be especially interesting in women that are
treated without surgical sampling of axillary LNs.
Our study has several important limitations. As we  did
not find any consensus on the division of axillary (level I)
LNs into separate subgroups, we used “homemade” classifi-
cation which was based on vascular anatomy and adopted
for the purposes of radiotherapy planning. We designated the
subgroup of pectoral LNs “located close to the chest wall”
which did not correspond to anatomical classification prin-
cipals but from our point of view could be important for fields
design. Comparison of different radiotherapy techniques
was performed after virtual positioning of SLN according to
anatomical landmarks (vessels, bony structures, muscles) and
subsequent modeling of radiation portals.
5.  Conclusion
SPECT-CT visualization of SLNs in women with early breast
cancer reveals different variants of their location in the axil-
lary region, which, in turn, affects the opportunity for SLN
tumoricidal-dose irradiation using different modifications of
tangential fields. Upon detection of “non-standard” SLN local-
ization (in the immediate vicinity of the chest wall or in the
projection of the lateral subgroup), the simultaneous irradia-
tion of the remaining breast tissue and axillary SLNs should
be performed using more  sophisticated radiation therapy
techniques, primarily IMRT. After a breast conserving treat-
ment without axillary surgery, simultaneous irradiation of the
remaining breast tissue with the axillary SLNs can be per-
formed after SPECT-CT visualization of SLNs as the necessary
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9. Alço  G, Iğdem SI, Ercan T, et al. Coverage of axillary lymph
nodes with high tangential fields in breast radiotherapy. Br J
Radiol 2010;83:1072–6.
